Selling Your Veterinary Practice to Lakefield Veterinary Group: A Vet’s 2026 Guide

Key takeaways

• Lakefield Veterinary Group is a family-owned veterinary practice acquisition company headquartered in Kent, Washington — founded in 2014 and rooted in the Pacific Northwest, with a network of more than 80 hospitals across roughly a dozen states.
• The Desmarais family holds majority ownership. Peloton Capital Management, a Toronto-based investment firm, made a strategic minority investment in 2024 — an unusual majority-family, minority-institutional structure in a buyer pool that is mostly majority private-equity-owned.
• A measured, relationship-first model is Lakefield’s defining feature. The platform expands deliberately and selectively rather than racing to maximum scale, and has recently extended eastward into the Southeast, Mid-Atlantic, and Florida from its Pacific Northwest base.
• Local independence and legacy preservation are central to Lakefield’s stated approach per company materials. Acquired practices typically keep their name, signage, and clinical culture — though sellers should still secure that in writing.
• The biggest negotiation surface is the gap between a relationship-first promise and a binding contract. The culture, autonomy, and brand-preservation language matters most precisely because the philosophy is so central to Lakefield’s pitch.
• The most reliable way to know what Lakefield — or any major buyer — would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. Lakefield is invited inside that rope on practices that fit their criteria — and when they bid against a curated group of qualified competitors, the number is reliably very different from what they would offer in a direct, single-bidder conversation.

When a vet hands me a Lakefield offer over dinner, the conversation usually opens on a warmer note than it does with most of the consolidators. Owners tend to say some version of “these people actually seem to care about my staff.” That impression isn’t an accident.

Lakefield has built its entire identity around being the buyer that moves slowly, listens first, and treats the seller’s practice as a legacy worth preserving rather than a unit to be plugged into a national machine.

So the first thing I do is gently separate the feeling from the contract. The relationship-first posture is real, and it’s a genuine differentiator in this market.

But a warm acquisition philosophy and a binding purchase agreement are two different documents, and the vet across the table needs both to be strong.

That tension is the through-line of every Lakefield conversation. The platform’s deliberate, measured, Pacific-Northwest-rooted approach is exactly what makes it appealing to owners who fear the fast national scalers.

The work is making sure the deal terms live up to the promise.

What follows is the same picture I’d lay out if a vet asked me what to do with a Lakefield offer. Who Lakefield is, how the majority-family ownership shapes the deal, what the measured expansion model means for sellers in 2026, where the negotiation leverage actually sits, and how to think about Lakefield against the rest of the US veterinary buyer pool in a properly run process.

Quick facts on Lakefield Veterinary Group

Lakefield Veterinary Group is a family-owned veterinary practice acquisition company headquartered in Kent, Washington, in the Pacific Northwest. The company was founded in 2014 and has grown deliberately over the decade since.

Lakefield’s network includes more than 80 hospitals across roughly a dozen US states per Lakefield company materials and 2025 trade announcements. The footprint is anchored in Washington and Oregon, with locations also in Texas, Arizona, Minnesota, Indiana, and Alaska, plus a recent push into the Southeast and Mid-Atlantic.

The ownership structure is one of Lakefield’s most distinctive features. The platform is majority-owned by the Desmarais family, the Canadian family office behind the deal, with Alexandre Desmarais serving as Executive Chairman per Lakefield company materials.

In July 2024, Peloton Capital Management — a Toronto-based private investment firm founded in 2018 — made a strategic minority investment in Lakefield per the transaction announcement. This is structurally different from most US veterinary consolidators, where a private equity sponsor holds the majority and drives the platform’s growth cadence.

The most important practical fact for a seller evaluating Lakefield. Lakefield expands deliberately, not at maximum speed. The majority-family ownership, the disciplined acquisition philosophy, and the relationship-first positioning all point to a buyer that grows selectively. For a seller, that can mean a more personal process and a buyer genuinely interested in fit, though it also means Lakefield is choosier about which practices and which geographies it pursues than the rapid national scalers.

What Lakefield actually pays for veterinary practices in 2026

The consistent pattern we see. When a multi-doctor practice receives a direct offer from any major buyer’s acquisition team — Lakefield included — the offer reflects the leverage the buyer perceives in the conversation. A single bidder facing no visible competition has no structural reason to put forward its strongest cash percentage, tightest earnout protections, or most explicit culture-preservation guarantees in the first conversation.

Inside a properly structured competitive process, where the buyer knows other qualified bidders are underwriting the same practice in parallel, those dimensions tend to move, sometimes meaningfully. The pattern is not unique to Lakefield.

It is the basic dynamic of how every major buyer in this market calibrates an offer to the room.

Lakefield does not publish a standard price sheet for any specific practice profile. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

EBITDA here is what your practice earns in pure operating profit, before taxes and accounting choices, and the multiple is the multiplier buyers apply to that profit to set the price.

The actual number for any specific practice depends heavily on whether other qualified buyers are at the table and on the specific profile of the practice. Lakefield participates in this competitive band when it bids on qualifying practices, with the specific offer on any given deal negotiated case by case under confidentiality.

For specialty and emergency hospitals, the broader market generally values these higher than comparable general practices per industry research. Lakefield’s footprint includes emergency and specialty hospitals, and the platform’s recent eastward acquisitions have included emergency-care additions, so Lakefield may bid for qualifying specialty or emergency practices when they fit the geographic and cultural profile.

For practices below the $2 million revenue threshold or single-doctor practices, the buyer pool generally shifts toward regional groups, smaller consolidators, and individual buyers. Lakefield’s measured model tilts toward practices that fit its existing geographic density and its relationship-driven culture, rather than a maximum-volume approach to deal sourcing.

The cash-at-close reality

For a buyer like Lakefield, the cash-at-close component of any offer sits inside a structure shaped by the majority-family ownership rather than a typical private-equity fund cycle. Per industry M&A commentary across the major buyer pool (Dechert LLP, Holland & Knight, Capstone Partners 2025-2026), the typical offer structure allocates the majority of total deal value to cash at close, with the remainder split among earnout and rollover or partnership equity.

Lakefield’s specific allocation on any given deal is negotiated case by case.

Earnout here means part of the sale price paid later, only if the practice hits agreed performance targets after closing. Rollover equity means keeping a slice of ownership in the new entity instead of taking all cash at close.

Where the ownership structure shows up in the cash-at-close conversation is in the time horizon behind a retained-equity component. A family-controlled platform with a minority institutional partner does not operate on the same fixed fund-life clock that drives many private-equity-majority consolidators toward a defined exit window.

That can change the underlying picture a seller is underwriting if rollover equity is on the table. It does not change the formula price or any put/call window on a specific deal, but the exit-timing logic behind a Lakefield rollover is worth understanding before you weigh it against a rollover into a fund-cycle platform.

A note on deal structure types in the current market

The broader US veterinary M&A market has shifted measurably toward partnership and joint-venture structures over the past 18 months per MB Law Firm’s 2025 healthcare M&A commentary. In these structures, the buyer acquires a majority stake (commonly 60 to 80 percent), the seller retains a minority stake (commonly 20 to 40 percent) as direct equity in the practice itself, and a contractual put/call mechanism defines the buyout date and formula price for the retained equity.

Lakefield’s specific posture on partnership versus 100-percent acquisition structures is determined case by case under confidentiality and is not publicly enumerated. What can be said is that Lakefield’s relationship-first, legacy-preservation positioning aligns naturally with partnership-style arrangements, where the selling owner stays meaningfully invested in the practice’s future.

Sellers evaluating a Lakefield offer should ask explicitly whether a partnership structure is available alongside a more traditional acquisition. Our PE pricing guide covers the structure-by-structure comparison in depth.

How Lakefield’s acquisition team operates

Lakefield’s corporate-development team reflects the platform’s measured personality. The sourcing emphasis has historically been on practices where the cultural fit is strong and where the geography fits Lakefield’s deliberate expansion map per Lakefield company materials, rather than on maximizing raw deal count.

The team works the standard mix of sourcing channels: direct relationships with practice owners, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries from owners drawn to Lakefield’s preserve-your-legacy positioning.

A practical implication for sellers. Because Lakefield leans into the relationship and the fit, the team tends to engage warmly and personally early in the conversation.

That is a genuine strength, and it is also exactly why a seller needs a disciplined process around the warmth.

The friendliest first conversation in the world does not, by itself, surface the strongest set of terms. Lakefield, like every institutional buyer, calibrates its full offer to the competitive reality it perceives.

When the team knows other qualified buyers are underwriting the same practice in parallel, the terms reflect that, which is why the value of a properly run competitive process is just as high with a relationship-first buyer as with any other.

How Lakefield integrates the practices it acquires

Lakefield’s integration model is built around its central promise: preserve the practice’s independence and local legacy while providing the operational support a standalone practice cannot easily build alone.

Local independence and legacy preservation. Per Lakefield company materials, the platform’s stated approach is to preserve the practice name, signage, clinical culture, and local identity. The integration is positioned as partnership and support rather than absorption.

This is one of the dimensions where Lakefield differs from Mars-affiliated entities such as VCA, which more commonly transition acquired practices to a Mars-network brand over time.

Operational and back-office support. Per Lakefield company materials, the platform provides recruiting, marketing, human resources, and back-office support across its network. The stated intent is to lift the administrative burden off the selling owner and the practice team so they can focus on medicine.

Recruiting and staffing. Lakefield emphasizes its ability to help practices attract and retain doctors and support staff, a meaningful benefit in a market where staffing is one of the hardest operational challenges independent owners face. The platform positions team continuity and culture preservation as part of its core promise.

Doctor relationships. Per industry M&A commentary on veterinary acquirers, selling owners commonly stay on as medical director or in a continuing clinical role for a multi-year post-close period, typically 3 to 5 years, with compensation structured as base salary plus production bonus. Lakefield’s specific post-sale employment terms for any given deal are negotiated case by case under the definitive purchase agreement.

The measured-integration upside, and the caveat. A deliberate platform tends to integrate at a pace that gives the practice room to breathe, which sellers consistently value. The caveat is the same one that applies to every stated philosophy: an integration promise carries the most weight when it is written into the definitive purchase agreement rather than left to good intentions.

Lakefield’s recent activity in 2025-2026

Lakefield enters 2026 as a deliberate, expanding acquirer in the US veterinary buyer pool. Capstone Partners‘ April 2026 Pet Sector M&A Update documents the broader sector’s continued activity, with both private-equity-backed and family-controlled acquirers running pipelines.

Lakefield’s own 2025 announcements describe a measured eastward expansion: an entry into Florida through a partnership in Naples, plus acquisitions in Virginia and Georgia that extended the platform into the Southeast and Mid-Atlantic from its Pacific Northwest base.

The pattern in those announcements is telling. Lakefield expanded into new regions through a small number of selective, relationship-driven deals rather than a rapid multi-state land-grab.

That cadence is consistent with the platform’s stated philosophy and with the disciplined approach its minority partner Peloton Capital has described.

The practical takeaway for an owner receiving 2026 Lakefield outreach: this is a buyer that grows by fit, not by volume. If your practice is in a market Lakefield is targeting and your culture aligns with theirs, you may find an unusually warm and personal process.

The discipline you bring to the terms is what turns that warmth into a strong outcome.

Have an offer from Lakefield Veterinary Group? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms, identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool. No upfront cost, no obligation.

How Lakefield compares to the other major buyers

If you’re considering Lakefield, you’re probably comparing them implicitly to the other buyers who would compete for your practice. Here’s how Lakefield stacks up across the dimensions that matter.

Versus the rapid national scalers (Western Veterinary Partners and similar fast-growth platforms). This is the sharpest contrast in the buyer pool. Where the rapid national scalers prioritize speed and breadth of footprint, Lakefield prioritizes deliberate, relationship-driven growth and cultural fit.

A seller whose top priority is a warm, measured process and strong legacy preservation may find Lakefield’s model especially appealing. A seller whose top priority is maximizing geographic options or speed to close may find the faster platforms a closer fit.

Both belong in a competitive process so the seller can compare them directly.

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic family-owned exception in the US veterinary buyer pool per Mars company disclosures, family-owned by Mars Inc. rather than private-equity-backed. The brand-handling difference is significant: Lakefield’s preserve-the-local-name approach contrasts with VCA’s historical brand-consolidation pattern under the VCA name.

Both may compete for qualifying practices in a structured sale process. Our Mars Veterinary Health buyer profile covers the Mars-specific dimensions in depth.

Versus NVA (JAB Holdings). NVA is owned by JAB Holdings, a privately held long-hold investment vehicle distinguishable from a private-equity fund cycle. Both NVA and Lakefield emphasize local practice branding per their respective company materials.

The key difference is scale and structure: NVA is a large, long-established network, while Lakefield is a mid-sized, family-controlled platform with a more selective footprint. Our NVA buyer profile walks through the NVA-specific dimensions.

Versus AmeriVet Veterinary Partners. AmeriVet has publicly emphasized partnership and joint-venture structures as a distinguishing feature of its acquisition approach. Both AmeriVet and Lakefield position around preserving practice identity, though the choice often comes down to whether the seller prefers a formal partnership structure with retained practice-level equity (AmeriVet) or a relationship-first, family-controlled platform (Lakefield).

Our AmeriVet buyer profile covers the partnership-model dimensions.

Versus VetCor (Harvest Partners). VetCor is one of the longest-tenured private-equity-backed platforms, with a refined integration playbook built over more than two decades. The contrast with Lakefield is institutional depth versus relationship-first deliberateness: VetCor offers a proven operational machine, while Lakefield offers a more personal, measured partnership.

Our VetCor buyer profile covers VetCor’s institutional-depth angle.

Versus the smaller and regional PE-backed groups. Each has its own integration philosophy and target profile. Smaller and newer groups sometimes pay more aggressively for practices that fill specific geographic gaps in their portfolio.

The right way to evaluate which buyer pays most, on the terms you actually care about, is to put all of them in a competitive process and let them surface their best offers in parallel.

What to negotiate before signing with Lakefield

Six priorities when negotiating with Lakefield’s acquisition team, with the culture-and-autonomy protective provisions as the highest-leverage category, precisely because they are the heart of what Lakefield promises.

Culture and legacy preservation in writing (highest priority). Lakefield’s entire pitch is built on preserving practice independence and local legacy. That makes the written commitment the single most important thing to nail down.

Negotiate explicit definitive-purchase-agreement language on practice name, signage, website, marketing materials, and clinical culture. A philosophy in marketing materials is reassuring; a binding contract clause is enforceable.

Post-sale clinical autonomy. Negotiate explicit language preserving your clinical autonomy. You make the medicine decisions, with a clear definition of which business decisions stay with you versus migrating to Lakefield’s operating structure over time.

Lakefield’s relationship-first posture makes this an easier conversation to start, but it still belongs in writing.

Earnout protective provisions. If the offer includes an earnout, negotiate protective provisions: no major operational changes without seller consent during the earnout period, a working capital floor, an explicit prohibition on shifting central services costs onto the practice, and a clear definition of what counts in the EBITDA calculation at the earnout date.

Cash at close percentage. Push for higher cash percentages. Every dollar shifted from contingent to cash at close is guaranteed money instead of conditional money.

A competitive process is what creates the leverage to move this number.

Rollover or partnership equity terms. If Lakefield’s offer includes rollover or a partnership stake, the family-controlled ownership structure means the exit-timing logic differs from a fund-cycle platform. Negotiate the standard protections regardless: defined liquidity windows, governance and information rights, minority-protection clauses, and anti-dilution provisions.

Non-compete scope. Non-competes commonly run several years and cover a defined geographic radius for all veterinary work. Negotiate shorter duration (1 to 2 years), a tighter radius (5 to 10 miles), or a carve-out for specific work you might continue post-employment.

The measured-expansion question, in depth

For sellers evaluating Lakefield specifically, the most useful frame is to think carefully about what a measured, relationship-first platform means for the post-sale practice life, in both directions.

The case for the measured model. Lakefield’s deliberate approach carries real advantages for the right seller:

• The acquisition process tends to be warmer and more personal, with genuine attention to cultural fit
• The integration generally moves at a pace that gives the practice room to adjust, rather than an immediate operational overhaul
• The legacy-preservation positioning aligns with owners who care deeply about what happens to their staff and their name
• The majority-family ownership avoids the fixed fund-life clock that pushes some private-equity-majority platforms toward a defined exit window
• The recent eastward expansion is selective, which signals a buyer choosing practices for fit rather than filling a quota

The case for treating the measured model as a negotiation surface. The flip side of a relationship-first philosophy is that warmth can substitute for rigor if the seller lets it:

• A stated philosophy is not a contractual commitment, and the gap between the two is exactly where sellers lose protection
• A selective buyer is choosier about geography and fit, so a single Lakefield conversation may not represent the full market for your practice
• The personal, friendly process can make a seller reluctant to run a competitive process, even though competition is what produces the strongest terms
• The mid-sized footprint means Lakefield’s operational support, while real, may differ in scope from the largest national platforms

The balance between these dimensions is exactly what gets negotiated in the definitive purchase agreement. Sellers who go into a Lakefield conversation with a refined sell-side process, and other qualified bidders at the table, consistently land more favorable positions on both sides of this balance than sellers who engage in a friendly one-on-one conversation and stop there.

Should I take a Lakefield offer or run a competitive process?

For Lakefield specifically, the value of the competitive process is concentrated in two places: turning the relationship-first promise into binding contract language, and confirming that a warm single-bidder offer actually reflects the full market for your practice. The headline cash percentage matters, but the culture, autonomy, and legacy-preservation clauses are where a measured buyer’s terms most need to be tested and tightened.

The mechanical reason is the same as for any major buyer. Without competition, no buyer has incentive to convert a warm philosophy into enforceable contract terms or to put forward its strongest cash percentage.

With competition, every term becomes negotiable because every bidder knows the seller has alternatives. For a relationship-first buyer like Lakefield, a structured process is what ensures the friendly conversation translates into a strong, written outcome rather than just a good feeling.

Lakefield participates in well-run competitive processes when invited. The Lakefield-specific dimensions, the legacy-preservation language, the clinical-autonomy carve-outs, the earnout protective provisions, get sharper attention from the Lakefield team when they know other qualified buyers are at the table on the same practice in the same window.

What our Elite Selling System actually does

For a Lakefield-affiliated transaction, our process is built around one specific reality: a relationship-first buyer makes sellers want to skip the competitive process, and that instinct is exactly what costs them.

Phase one, the promise-to-contract audit. Before any bidder packet goes out, we map Lakefield’s stated philosophy against what its draft definitive purchase agreement would actually commit to in writing. Where does the legacy-preservation promise sit in the contract versus the marketing materials?

What clinical-autonomy language is in the draft, and what is missing? What does the post-sale operating structure default to, and where can the seller carve out protections?

This audit identifies the gap between warmth and enforceability before the process opens.

Phase two, the bidder mix. From the 42-plus named veterinary consolidators TE actively tracks, we invite only the ones that legitimately compete with Lakefield for this specific practice. The legacy-preservation buyers (NVA, AmeriVet, the regional platforms with explicit brand-preservation positioning) compete on that dimension.

The strategic family-owned alternative (Mars, where the practice fits Mars’s criteria) competes on long-hold posture. The faster national scalers compete on footprint and speed.

The right mix is typically 5 to 7 invited bidders, each genuinely competing on a dimension a Lakefield-minded seller cares about.

Phase three, the term-by-term comparison. Bidders return their full term sheets, not just the headline numbers. The seller sees side-by-side comparisons across cash-at-close, earnout structure and protective provisions, rollover or partnership terms, non-compete scope, post-sale role, culture-and-legacy commitments, and integration approach.

The seller chooses on the dimensions that matter, sometimes the buyer with the warmest cultural fit (which may well be Lakefield), sometimes the buyer with the highest headline number, sometimes the buyer with the strongest written protections.

The economic result holds across deal types: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes, typically multiple seven figures, sometimes more, than the same practice would have cleared by signing the original direct term sheet without exploring the field.

Closing thought

The honest read on Lakefield Veterinary Group: it is one of the more genuinely relationship-first buyers in the US veterinary pool, a family-controlled platform that grows deliberately from its Pacific Northwest base and treats legacy preservation as a core promise rather than a marketing afterthought. For the right seller, that model is a real and rare fit.

What separates a well-negotiated Lakefield outcome from a mediocre one is not whether the process feels warm, it usually will, but whether the warmth gets written into the contract. The legacy-preservation language, the clinical-autonomy carve-outs, the earnout protective provisions, the cash-at-close percentage.

Those terms determine whether Lakefield’s deliberate, relationship-driven philosophy actually protects you across the post-close years.

If you’ve received a Lakefield offer, or if Lakefield’s team has reached out to start a conversation, the highest-leverage move is to understand how the rest of the field would structure the same practice, and to make sure the relationship-first promise becomes enforceable language, before committing to anything. Get a Free Practice Value Estimate and we’ll lay out the same comparison we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research. capstonepartners.com
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary. octus.com
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications. dechert.com
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications. hklaw.com
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

Lakefield Veterinary Group and investor materials

6. Lakefield Veterinary Group. Who We Are and Our Story. Lakefield company materials, 2024-2026. lakefieldvet.com
7. Peloton Capital Management. Peloton Capital Management Invests in Lakefield Veterinary Group. July 2024 transaction announcement. pelotoncapitalmanagement.com
8. Stoel Rives LLP. Lakefield Veterinary Group Finalizes Investment by Peloton Capital Management. 2024. stoel.com
9. Business Wire. Lakefield Veterinary Group Expands to Florida, Strengthens East Coast Presence. July 2025. businesswire.com
10. Business Wire. Lakefield Veterinary Group Earns Spot on the Inc. 5000 List of Fastest-Growing Companies. August 2025. businesswire.com

Veterinary practice operations, benchmarks, and profession data

11. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research. ivet360.com
12. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research. avma.org
13. dvm360. Clinic center: From New York to Hawaii, veterinary organizations grow across the US. dvm360 trade coverage. dvm360.com